MX2021000235A - Anticuerpo anti-abeta, fragmento de union a antigeno del mismo y aplicacion del mismo. - Google Patents

Anticuerpo anti-abeta, fragmento de union a antigeno del mismo y aplicacion del mismo.

Info

Publication number
MX2021000235A
MX2021000235A MX2021000235A MX2021000235A MX2021000235A MX 2021000235 A MX2021000235 A MX 2021000235A MX 2021000235 A MX2021000235 A MX 2021000235A MX 2021000235 A MX2021000235 A MX 2021000235A MX 2021000235 A MX2021000235 A MX 2021000235A
Authority
MX
Mexico
Prior art keywords
antigen
binding fragment
abeta antibody
application
disease
Prior art date
Application number
MX2021000235A
Other languages
English (en)
Inventor
Ling Zhang
Hua Ying
Weikang Tao
Qiyue Hu
Jiakang Sun
Jinping Shi
Xiaomin Zhang
Original Assignee
Jiangsu Hengrui Medicine Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Medicine Co filed Critical Jiangsu Hengrui Medicine Co
Publication of MX2021000235A publication Critical patent/MX2021000235A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Genetics & Genomics (AREA)
  • Psychiatry (AREA)
  • Molecular Biology (AREA)
  • Psychology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Anticuerpo anti-Abeta murino, quimérico o humanizado que tiene una región CDR específica, un fragmento de unión a antígeno del mismo, una composición farmacéutica del mismo y el uso del mismo. Uso de un anticuerpo anti-Abeta humanizado para la preparación de medicamentos para el tratamiento de una enfermedad o trastorno (como la enfermedad de Alzheimer) causados por la proteína beta amiloide.
MX2021000235A 2018-07-17 2019-07-16 Anticuerpo anti-abeta, fragmento de union a antigeno del mismo y aplicacion del mismo. MX2021000235A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201810782196 2018-07-17
PCT/CN2019/096159 WO2020015637A1 (zh) 2018-07-17 2019-07-16 抗Abeta抗体、其抗原结合片段及应用

Publications (1)

Publication Number Publication Date
MX2021000235A true MX2021000235A (es) 2021-03-25

Family

ID=69163622

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021000235A MX2021000235A (es) 2018-07-17 2019-07-16 Anticuerpo anti-abeta, fragmento de union a antigeno del mismo y aplicacion del mismo.

Country Status (10)

Country Link
US (1) US20210371506A1 (es)
EP (1) EP3819311A4 (es)
JP (1) JP7436449B2 (es)
KR (1) KR20210032408A (es)
CN (1) CN111094340B (es)
AU (1) AU2019304384A1 (es)
BR (1) BR112020027055A2 (es)
CA (1) CA3106116A1 (es)
MX (1) MX2021000235A (es)
WO (1) WO2020015637A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116348487A (zh) 2020-07-23 2023-06-27 欧萨尔普罗席纳有限公司 抗淀粉样β抗体
CN117624358B (zh) * 2024-01-26 2024-04-12 南京诺唯赞医疗科技有限公司 Aβ1-40特异性抗体及其在阿尔茨海默症辅助诊断试剂盒的应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
EP1308461A3 (en) 1993-01-25 2004-02-11 Takeda Chemical Industries, Ltd. Antibodies to beta-amyloids or their derivatives and use thereof
CA2286305A1 (en) 1997-04-09 1998-10-15 Mindset Ltd. Recombinant antibodies specific for beta-amyloid ends, dna encoding and methods of use thereof
EP1432444A4 (en) 2001-08-17 2005-11-02 Lilly Co Eli ANTI-BETA ANTIBODIES
AR038568A1 (es) 2002-02-20 2005-01-19 Hoffmann La Roche Anticuerpos anti-a beta y su uso
CN1849139A (zh) * 2002-10-09 2006-10-18 里纳特神经系统学公司 使用针对淀粉样β肽的抗体及其组合物治疗阿尔茨海默氏病的方法
JP2006519762A (ja) * 2002-10-09 2006-08-31 ライナット ニューロサイエンス コーポレイション アミロイドβペプチド及びその組成物に対する抗体を使用して、アルツハイマー病を治療する方法
ATE468886T1 (de) 2003-02-10 2010-06-15 Applied Molecular Evolution Abeta-bindende moleküle
PE20050627A1 (es) * 2003-05-30 2005-08-10 Wyeth Corp Anticuerpos humanizados que reconocen el peptido beta amiloideo
EP2465872A3 (en) * 2004-10-25 2012-12-19 Merck Sharp & Dohme Corporation Anti-ADDL antibodies and uses thereof
AU2006208226A1 (en) * 2005-01-24 2006-08-03 Amgen Inc. Humanized anti-amyloid antibody
UA95933C2 (ru) * 2005-11-30 2011-09-26 Эбботт Леборетриз АНТИТЕЛА ПРОТИВ ГЛОБУЛОМЕРА Ab (20-42), ИХ АНТИГЕНСВЯЗУЮЩИЕ ЧАСТИ, СООТВЕТСТВУЮЩИЕ ГИБРИДОМЫ, НУКЛЕИНОВЫЕ КИСЛОТЫ, ВЕКТОРЫ, КЛЕТКИ-ХОЗЯЕВА, СПОСОБЫ ПОЛУЧЕНИЯ УКАЗАННЫХ АНТИТЕЛ, КОМПОЗИЦИИ, КОТОРЫЕ СОДЕРЖАТ УКАЗАННЫЕ АНТИТЕЛА, ПРИМЕНЕНИЕ УКАЗАННЫХ АНТИТЕЛ И СПОСОБЫ ИСПОЛЬЗОВАНИЯ УКАЗАННЫХ АНТИТЕЛ
UA102368C2 (ru) * 2005-12-12 2013-07-10 Ас Иммуне С.А. СПЕЦИФИЧЕСКИЕ В ОТНОШЕНИИ β-АМИЛОИДА 1-42 МОНОКЛОНАЛЬНЫЕ АНТИТЕЛА, КОТОРЫЕ ИМЕЮТ ТЕРАПЕВТИЧЕСКИЕ СВОЙСТВА
RU2429244C2 (ru) 2006-03-23 2011-09-20 Байоарктик Ньюросайенс Аб Улучшенные селективные в отношении протофибрилл антитела и их применение
ES2484967T3 (es) * 2006-03-30 2014-08-12 Glaxo Group Limited Anticuerpos contra el péptido beta-amiloide
MX2009000476A (es) 2006-07-14 2009-01-28 Ac Immune Sa Anticuerpo humanizado contra beta amiloide.
HUE033325T2 (en) 2007-01-05 2017-11-28 Univ Zuerich Anti-beta-amyloid binder antibodies and their use
NZ601858A (en) * 2007-10-05 2014-03-28 Genentech Inc Methods and compositions for diagnosis and treatment of amyloidosis
AU2008343855B2 (en) * 2007-12-21 2013-08-15 Amgen Inc. Anti-amyloid antibodies and uses thereof
ES2641612T3 (es) * 2009-04-17 2017-11-10 Immunas Pharma, Inc. Anticuerpos que se unen específicamente a oligómeros de beta A y uso de los mismos
CA2817973C (en) 2010-10-15 2019-06-25 The Board Of Regents Of The University Of Texas System Antibodies that bind amyloid oligomers
LT2906597T (lt) * 2012-10-15 2020-07-10 Medimmune Limited Antikūnai, atpažįstantys beta amiloidą
JP2019510474A (ja) 2016-02-05 2019-04-18 ジエンス ヘンルイ メデイシンカンパニー リミテッドＪｉａｎｇｓｕ Ｈｅｎｇｒｕｉ Ｍｅｄｉｃｉｎｅ Ｃｏ．，Ｌｔｄ． トロンビン抗体、その抗原結合フラグメント及び医薬用途
CN116333108A (zh) * 2016-07-18 2023-06-27 英属哥伦比亚大学 淀粉样蛋白β的抗体

Also Published As

Publication number Publication date
EP3819311A1 (en) 2021-05-12
JP7436449B2 (ja) 2024-02-21
JP2021529543A (ja) 2021-11-04
EP3819311A4 (en) 2022-08-17
WO2020015637A1 (zh) 2020-01-23
CN111094340A (zh) 2020-05-01
CN111094340B (zh) 2022-11-22
AU2019304384A1 (en) 2021-01-28
CA3106116A1 (en) 2020-01-23
KR20210032408A (ko) 2021-03-24
BR112020027055A2 (pt) 2021-04-06
US20210371506A1 (en) 2021-12-02

Similar Documents

Publication Publication Date Title
MX2021005396A (es) Anticuerpo anti-cd73, fragmento de union a antigeno y aplicacion del mismo.
MX2021011489A (es) Anticuerpo anti-claudina 18.2 y utilizacion del mismo.
ZA202004701B (en) Anti-b7-h4 antibody, antigen-binding fragment thereof and pharmaceutical use thereof
MY184154A (en) Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof
EA201992163A1 (ru) АНТИТЕЛА К БЕТА-АМИЛОИДНОМУ ПЕПТИДУ N3pGlu И ИХ ПРИМЕНЕНИЕ
MX2022013163A (es) Anticuerpo contra nectin-4 y aplicacion del mismo.
MX2020007406A (es) Anticuerpo pd-l1, fragmento de union al antigeno del mismo y uso farmaceutico del mismo.
EA201790342A1 (ru) Антитела к trem2 и способы их применения
JOP20170004B1 (ar) الأجسام المضادة لببتيد بيتا النشوي مضاد N3pGlu واستخداماته
MX2021009041A (es) Anticuerpo anti-pd-1, fragmento de union a antigeno del mismo y uso farmaceutico del mismo.
MX2021002531A (es) Anticuerpo anti-cd38, fragmento de union al antigeno y uso farmaceutico.
MX2019015914A (es) Anticuerpos quiméricos para el tratamiento de enfermedades por deposición de amiloide.
MX2021003168A (es) Anticuerpo anti-ox40, fragmento de union al antigeno del mismo y uso farmaceutico.
MX2019014375A (es) Anticuerpo anti-cd40, fragmento de union a antigeno del mismo, y uso medico del mismo.
MA39821A (fr) Molécules de liaison spécifiques de l'il-21 et leurs utilisations
ZA202202363B (en) Antibodies against ilt2 and use thereof
MX2021007235A (es) Tubulisinas y conjugados de proteina-tubulisina.
MX2018009264A (es) Anticuerpo de trombina, fragmento de antigeno y sus usos farmaceuticos.
MX2021000235A (es) Anticuerpo anti-abeta, fragmento de union a antigeno del mismo y aplicacion del mismo.
MX2018004406A (es) Anticuerpo monoclonal bactericida contra la klebsiella pneumoniae.
EA202190183A1 (ru) Антитела к siglec-5 и способы их применения
MX2020010119A (es) Anticuerpo anti-cd27, fragmento de union a antigeno del mismo y uso medico del mismo.
EA201892313A1 (ru) Гуманизированные антитела против clever-1 и их применение
MX2021008760A (es) Anticuerpo anti-cd79b, fragmento de union a antigeno del mismo y uso farmaceutico del mismo.
MX2017011480A (es) Anticuerpo de anti-esclerostina, fragmento de union a antigeno y uso medico del mismo.